
Paul N. Fiorilli
VerifiedUniversity of Pennsylvania · Rehabilitation Medicine
Active 2008–2024
Research topics
- Medicine
- Cardiology
- Internal medicine
- Intensive care medicine
Selected publications
Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study
European Heart Journal · 2023 · 238 citations
- Medicine
- Cardiology
- Internal medicine
BACKGROUND AND AIMS: For patients with symptomatic, severe tricuspid regurgitation (TR), early results of transcatheter tricuspid valve (TV) intervention studies have shown significant improvements in functional status and quality of life associated with right-heart reverse remodelling. Longer-term follow-up is needed to confirm sustained improvements in these outcomes. METHODS: The prospective, single-arm, multicentre TRISCEND study enrolled 176 patients to evaluate the safety and performance of transcatheter TV replacement in patients with ≥moderate, symptomatic TR despite medical therapy. Major adverse events, reduction in TR grade and haemodynamic outcomes by echocardiography, and clinical, functional, and quality-of-life parameters are reported to one year. RESULTS: Enrolled patients were 71.0% female, mean age 78.7 years, 88.0% ≥ severe TR, and 75.4% New York Heart Association classes III-IV. Tricuspid regurgitation was reduced to ≤mild in 97.6% (P < .001), with increases in stroke volume (10.5 ± 16.8 mL, P < .001) and cardiac output (0.6 ± 1.2 L/min, P < .001). New York Heart Association class I or II was achieved in 93.3% (P < .001), Kansas City Cardiomyopathy Questionnaire score increased by 25.7 points (P < .001), and six-minute walk distance increased by 56.2 m (P < .001). All-cause mortality was 9.1%, and 10.2% of patients were hospitalized for heart failure. CONCLUSIONS: In an elderly, highly comorbid population with ≥moderate TR, patients receiving transfemoral EVOQUE transcatheter TV replacement had sustained TR reduction, significant increases in stroke volume and cardiac output, and high survival and low hospitalization rates with improved clinical, functional, and quality-of-life outcomes to one year. Funded by Edwards Lifesciences, TRISCEND ClinicalTrials.gov number, NCT04221490.
Current interventional therapies in acute pulmonary embolism
Progress in Cardiovascular Diseases · 2021 · 7 citations
- Medicine
- Intensive care medicine
- Cardiology
Frequent coauthors
- 87 shared
Karl E. Minges
- 84 shared
Jeptha P. Curtis
Yale University
- 84 shared
Jeph Herrin
Yale University
- 82 shared
John C. Messenger
University of Colorado Denver
- 82 shared
Brahmajee K. Nallamothu
- 82 shared
Henry H. Ting
Jacksonville College
- 82 shared
Rebecca S. Lipner
American Board of Internal Medicine
- 82 shared
Joseph Brennan
- Resume-aware match score
- Save to shortlist
- AI-drafted outreach
See your match with Paul N. Fiorilli
PhdFit ranks faculty by your research interests, methods, and publications — grounded in their actual work, not templates.
- Free to start
- No credit card
- 30-second signup